[HTML][HTML] Nanoparticle-mediated combination therapy: two-in-one approach for cancer
Cancer represents a group of heterogeneous diseases characterized by uncontrolled
growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a …
growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a …
[HTML][HTML] Molecular targets, therapeutic agents and multitasking nanoparticles to deal with cancer stem cells: A narrative review
There is increasing evidence that malignant tumors are initiated and maintained by a sub-
population of tumor cells that have similar biological properties to normal adult stem cells …
population of tumor cells that have similar biological properties to normal adult stem cells …
Quercetin and 5-Fu Loaded Chitosan Nanoparticles Trigger Cell-Cycle Arrest and Induce Apoptosis in HCT116 Cells via Modulation of the P53/P21 Axis
Nanoparticles (NPs) are encapsulating agents that exist in the nanometer range. They can
be classified into different classes based on their properties, shapes, or sizes. Metal NPs …
be classified into different classes based on their properties, shapes, or sizes. Metal NPs …
2020 innovation‐based optimism for lung cancer outcomes
Lung cancer is the leading cause of cancer death in both males and females in the US and
worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung …
worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung …
[HTML][HTML] Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma
Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with
aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are …
aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are …
Paclitaxel and erlotinib-co-loaded solid lipid core nanocapsules: assessment of physicochemical characteristics and cytotoxicity in non-small cell lung cancer
Purpose Lung cancer is the leading cause of cancer-related deaths. The aim of this study
was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a …
was to design solid lipid core nanocapsules (SLCN) comprising a solid lipid core and a …
[HTML][HTML] Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase III randomized controlled trials evaluating the first …
K Nakashima, N Horita, K Nagai, S Manabe… - Journal of Thoracic …, 2016 - Elsevier
Introduction Recent improvements in chemotherapy agents have prolonged postprogression
survival of non–small cell lung cancer. Thus, primary outcomes other than overall survival …
survival of non–small cell lung cancer. Thus, primary outcomes other than overall survival …
Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data
T Gan, Z Xie, R Tang, T Zhang, D Li, Z Li… - Tumor …, 2017 - journals.sagepub.com
MicroRNAs have been reported to be involved in various biological processes. Here, we
performed a systematic analysis to explore the clinical value and potential molecular …
performed a systematic analysis to explore the clinical value and potential molecular …
Emerging advances in nanomedicine for breast cancer immunotherapy: Opportunities and challenges
MZ Ahmad, AS Alasiri, MY Alasmary, MM Abdullah… - …, 2022 - Taylor & Francis
Breast cancer is one of the most common causes of cancer-related morbidity and mortality in
women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers …
women worldwide. Early diagnosis and an appropriate therapeutic approach for all cancers …
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition
Y Li, Y Pan, W Wu, S Mao, J Sun, Y Zhao, J Dong… - Medical oncology, 2016 - Springer
Erlotinib is effective in NSCLC patients with known drug-sensitizing EGFR mutations, but its
clinical efficacy in patients with wild-type EGFR or acquired resistance to erlotinib remains …
clinical efficacy in patients with wild-type EGFR or acquired resistance to erlotinib remains …